HomeACQUISITIONS and MERGERS

ACQUISITIONS and MERGERS

TriMas Closes on Acquisition of Omega

The addition of Omega further expands TriMas Packaging’s Pharmaceutical & Nutraceutical product offering into supporting medical device contract development manufacturing customers.

Quilvest Acquires Majority Interest in UrgentMED

Quilvest is partnering with UrgentMED's co-founders, Dr. Jacob Rastegar, Dr. Morris Kokhab, and Dr. Pejman Bolourian, who will each remain significant shareholders and will continue to lead the business going forward. 

Trajan Group Acquires Axel Semrau GmbH

Trajan's automation business and Axel Semrau have worked in close cooperation for several years.

Pacur To Acquire CAROLEX To Expand Global Position And Customer Reach

Pacur is the leading supplier of extruded PETG sheet used principally to provide rigid, high-performance packaging for medical devices.

Clinical Ink Acquires Digital Artefacts

Digital Artefacts is a digital endpoint-based technology company with an unrivaled modular platform for complex cognitive, behavioral, & physiological data capture.

Philips to Acquire Cardiologs

Cardiologs will further strengthen Philips’ cardiac monitoring and diagnostics offering with innovative software technology, electrocardiogram (ECG) analysis and reporting services

Avantor® Completes Acquisition of Masterflex®

"The acquisition of Masterflex extends Avantor's single-use offering and gives us a complete end-to-end solution for aseptic fluid transfer throughout the bioproduction workflow," said Michael Stubblefield, President and CEO of Avantor.

ZEUS Scientific Acquires Synthetic Peptides from Sheba Medical Center’s Tech Transfer Co.

The company intends to utilize these innovative multi-epitope citrullinated peptides for the development of a new generation of immunoassays designed to measure autoantibodies as an aid in the diagnosis of Rheumatoid Arthritis.

Hawkeye Announces Letter of Intent to Acquire Six15 Technologies

Rich Ryan, CEO of Six15, commented, "We view the anticipated Agreement and subsequent capital raise as the final element needed to catalyze the hyper-growth phase of our business plan. We further believe our evolving narrative will be well-suited to attract and build long-term investor interest as a public company."
Exit mobile version